The changes in quantitative HCV RNA titers during interferon alpha 2B therapy in patients with chronic hepatitis C infection

American Journal of Gastroenterology

Volumn 93, Issue 4, 1998, Pages 601-605

  Tong, Myron J ^a   Blatt, Lawrence M ^b   Conrad, Andrew ^b   Hur, Yuri ^b   Russell, James ^b   El Farra, Naveen S ^b   Co, Ruth L ^b  

^a HUNTINGTON MEMORIAL HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; VIRUS RNA;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD LEVEL; DRUG RESPONSE; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RELAPSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADOLESCENT; ADULT; AGED; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; RNA, VIRAL;

EID: 0032056308     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.1998.172_b.x     Document Type: Article

References (13)

1. 1. Sherlock S. Viral hepatitis. Lancet 1992;339:802.
2. 2. Tong MJ, Lee SY, Hywang SJ, et al. Evidence for hepatitis C viral infection in patients with primary hepatocellular carcinoma. West J Med 1994;160:133-8.
3. 3. Belle SH, Beringer KC, Detre KM. An update on liver transplantation in the United States: Recipient characteristics and outcome. Clin Transplant 1995;1575-8.
4. 4. Hoofnagle JH, Mullen KD, Jones DB, et al. Treatment of chronic non-A, non-b hepatitis with recombinant human alfa Interferon. A preliminary report. N Engl J Med 1986;315:1575-8.
5. 5. Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. N Eng J Med 1989;321:1501-6.
6. 6. Marcellin P, Boyer N, Giostra E, et al. Recombinant human alpha Interferon in patients with chronic non A and non-B hepatitis: A multicenter randomized controlled trial from France. Hepatology 1991;101:497-502.
7. 7. Causse X, Godinot H, Chevallier M, et al. Comparison of 1 or 3 MU of Interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology 1991;101:497-502.
8. 8. Hawkins A, Davidson F, Simmonds P. Comparison of plasma virus loads among individuals infected with Hepatitis C virus (HCV) genotypes 1, 2 and 3 by quantiplex HCV RNA assay versions 1 and 2, Roche Monitor Assay and an in-house limiting dilution method. J Clin Microbiol 1997;35:187-92.
9. 9. Tong MJ, Blatt LM, McHutchison J, et al. Prediction of response during Interferon alfa 2B therapy in chronic hepatitis C patients using viral and biochemical characteristics: A comparison. Hepatology 1997; 26:1640-5.
10. 10. Stuyver L, Rossau R, Wyscur A, et al. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probing assay. J Gen Virol 1993;74:1093-1102.
11. 11. Simmonds P, Alberti P, Alter HJ, et al. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 1994;19: 1321-4.
12. 12. Pockros PJ, Tong MJ, Lee WM, et al. Relationship between biochemical and virologic response to type I Interferon therapy of chronic HCV infection. Hepatology 1996;24:155A (abstract).
13. 13. Pockros P, Bain E, Hunter E, et al. RT-PCR and BDNA assays for hepatitis C virus correlate at high but not low viral titers. Gastroenterology 1997;112:A 1306 (abstract).